Product Description
Aniracetam is believed to be therapeutically useful for enhancing cognition, alleviating anxiety, and treating various neurodegenerative conditions. Physiologically, aniracetam enhances both glutamatergic neurotransmission and long-term potentiation. Aniracetam is a piracetam analog that has few reported side effects (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4123976/)
Mechanisms of Action: AMPA Modulator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Colombia | Egypt | Greece | Italy
Approved Indications: None
Known Adverse Events: None
Company: Longhua Hospital of Shanghai University of Traditional Chinese Medicine
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ChiCTR2000037418 | N/A |
Not yet recruiting |
Unknown |
2022-09-30 |